Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
Pylarify Injection Modification to Correct Obligation # is a federal award for 246-Network Contracting Office 6 (36C246) held by Progenics Pharmaceuticals Inc. Estimated value $1M ($1M obligated). Current period of performance ends Jan 31, 2027. Place of performance: NORTH BILLERICA MA.
Pylarify injection modification to correct obligation #. Latest action is a modification.
Recompete timing
PublicCurrent PoP ends Jan 31, 2027 (106 days remaining). Agencies typically plan 12–18 months ahead — at 3.5 months out, that window is already open. The buying decision is likely already in motion.
Want the durability read on 36C24626N0396? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordProgenics Pharmaceuticals Inc — $95.0M obligated across 149 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 36C24626N0396?
36C24626N0396 (Pylarify injection modification to correct) is a 246-Network Contracting Office 6 (36C246) award with a potential value of $1M, currently held by Progenics Pharmaceuticals Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 36C246-26-N-0396?
36C246-26-N-0396 is the dashed form of PIID 36C24626N0396 (Pylarify injection modification to correct), held by Progenics Pharmaceuticals Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 36C24626N0396?
246-Network Contracting Office 6 (36C246) awarded 36C24626N0396 to Progenics Pharmaceuticals Inc (potential $1M).
Who is the incumbent on 36C24626N0396?
Progenics Pharmaceuticals Inc is the incumbent with $95.0M across 149 related awards in SCOUT’s public footprint. The current period of performance ends Jan 31, 2027.
When does Progenics Pharmaceuticals Inc’s 36C24626N0396 come up for recompete?
SCOUT tracks a period-of-performance end of Jan 31, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 36C24626N0396? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.